The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The genomic definition of ultra-high-risk multiple myeloma
Jill Corre, PhD, The Cancer University Institute of Toulouse Oncopole, Toulouse, France, discusses the genomic criteria for defining ultra-high-risk multiple myeloma. This condition is characterized by specific genetic mutations, such as TP53 biallelic inactivation, biallelic deletion of 1p32, and certain t(4;14) translocations. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
